ADK.V - DIAGNOS Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1950
+0.0050 (+2.63%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.1900
Open0.1900
Bid0.1850 x 0
Ask0.1950 x 0
Day's Range0.1900 - 0.1950
52 Week Range0.1000 - 0.4800
Volume23,262
Avg. Volume53,668
Market Cap11.966M
Beta (5Y Monthly)2.94
PE Ratio (TTM)N/A
EPS (TTM)-0.0850
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.75
  • GlobeNewswire

    DIAGNOS Announces Stock Options Grant

    BROSSARD, Quebec, March 27, 2020 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues.

  • GlobeNewswire

    DIAGNOS Will Utilize its Artificial Intelligence Medical Platform FLAIRE in Response to the “US White House - Call to Action” to Analyse and Transform COVID-19 Data into Clinical Knowledge

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces that it is participating in the “Call to Action” initiative implemented by the White House Office of Science and Technology Policy. DIAGNOS has accessed a significant dataset with the objective of analysing these medical documents with its AI Medical Platform, called FLAIRE, in order to identify key factors that could assist in the battle against the Coronavirus. In response to the COVID-19 pandemic, the White House and a coalition of leading research groups have prepared the COVID-19 Open Research Dataset (CORD-19).

  • GlobeNewswire

    DIAGNOS Announces Closing of Oversubscribed $2.1 Million Private Placement

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces that it has completed the non-brokered private placement previously announced on February 24th, 2020. The Corporation issued a total of 11,901,995 common shares of the Corporation (each a “Share”) at a price of $0.18 per Share, for gross proceeds of $2,142,360.16 (the “Private Placement”).

  • GlobeNewswire

    DIAGNOS Announces Private Placement of Common Shares

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces that it has undertaken to complete a non-brokered private placement (“Private placement”) of up to 9,722,223 common shares of the Corporation (each a “Share”) to be issued at a price of $0.18 per Share, for gross proceeds of up to $1,750,000. The proceeds from the Private placement will mainly be used to fund sales and marketing as well as administrative expenses. In connection with the Private placement, the Corporation may pay certain qualified person(s) a commission in the form of (i) cash equal to 8% on the proceeds from subscribers referred by the qualified person, and (ii) a number of broker warrants equal to 8% of the Shares issued to subscribers referred by the qualified person.

  • Trade Alert: Tristram Coffin At DIAGNOS Inc. (CVE:ADK), Has Just Spent CA$74k Buying Shares
    Simply Wall St.

    Trade Alert: Tristram Coffin At DIAGNOS Inc. (CVE:ADK), Has Just Spent CA$74k Buying Shares

    Even if it's not a huge purchase, we think it was good to see that Tristram Coffin, a DIAGNOS Inc. (CVE:ADK) insider...

  • GlobeNewswire

    DIAGNOS Announces Shares for Debt Transaction

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the issuance of 2,222,222 common shares of the Corporation (each a “Share”), at a deemed price of $0.18 per Share, in settlement for an outstanding unsecured loan of $400,000. Satisfying this outstanding indebtedness with shares was undertaken in order to preserve the Corporation’s cash for operational purposes. The holder of the loan eligible to receive common shares as part of the shares for debt transaction is considered a “related party” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

  • GlobeNewswire

    DIAGNOS Announces Closing of Private Placement

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces that it has completed the non-brokered private placement previously announced on February 5, 2020, of 4,547,110 common shares of the Corporation (each a “Share”) issued at a price of $0.18 per Share, for gross proceeds of $818,479.80 (the “Private placement”).

  • GlobeNewswire

    DIAGNOS Successfully Completes ISO 13485 / MDSAP Surveillance Audit

    Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”We”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that its quality management system continues to fully comply with the applicable regulatory requirements for medical devices. As part of the requirements for the commercialization of our flagship product CARA from Health Canada, the Food and Drug Agency in the US (FDA) and CE in Europe, DIAGNOS must undergo thorough statutory annual quality compliance audits, such as the Medical Device Single Audit Program (MDSAP).

  • GlobeNewswire

    DIAGNOS AI based clinical Eye Test for Diabetic Retinopathy Demonstrates Exceptional Performance at the CHUM, expands for an Additional Six Months

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the extension of its technological platform for the automated detection of Diabetic Retinopathy at the CHUM (Centre hospitalier de l’Université de Montréal) until the end of June 2020. Launched in June 2018 in collaboration with the ophthalmology and endocrinology department, the technology showcase has so far allowed several hundred diabetic patients from the CHUM to access cutting edge screening technology.

  • Did You Manage To Avoid DIAGNOS's (CVE:ADK) Devastating 88% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid DIAGNOS's (CVE:ADK) Devastating 88% Share Price Drop?

    It's not possible to invest over long periods without making some bad investments. But really bad investments should...

  • GlobeNewswire

    DIAGNOS Announces a New Strategic Partnership Agreement in Costa Rica

    Diagnos Inc. (“DIAGNOS”, “the Corporation” or ”We”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today a new partnership agreement with a local firm (the “Partner”) to market DIAGNOS’ AI solutions in Costa Rica.

  • GlobeNewswire

    DIAGNOS Announces Collaborative Agreement in the North American Borderplex Region

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its CARA platform based on Artificial Intelligence (AI), announces today a new collaborative agreement with a local partner in the North American Borderplex region. “After learning about DIAGNOS’ impressive AI solution in the prevention of vision loss, we’re today partnering with DIAGNOS to make accessible its CARA services to mass population in this region of Mexico and the southern part of the United States where diabetes, and its consequences such as blindness, is a heavy health concern”, said the partner.

  • GlobeNewswire

    DIAGNOS Welcomes Mr. Francis Bellido to its Board of Directors

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment, effective November 27, 2019, of Mr. Francis Bellido to the Corporation’s board of directors (the “Board”). Mr. Bellido has spent his career overseeing and leading the development of several organizations in the healthcare industry.

  • GlobeNewswire

    DIAGNOS Announces Short Term Financing

    BROSSARD, Quebec, Nov. 26, 2019 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through.

  • GlobeNewswire

    DIAGNOS and its Local Partner Selected Following a Competitive Bid from the Mexican Government

    BROSSARD, Québec, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its CARA platform based on Artificial Intelligence (AI) announces today, through its local partner in Mexico, that it has been selected after a competitive bid from the Mexican Government for screening services among diabetic patients. “After successful results in 2016 and 2017, today we are very happy that the new Federal Government of Mexico has accepted DIAGNOS’ solution to continue monitoring the diabetic patients for the avoidance of blindness caused by diabetes.

  • GlobeNewswire

    DIAGNOS Appoints New Chairman of the Board of Directors

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Mr. François Côté as Chairman of the Corporation’s board of directors (the “Board”), effective today, in replacement of Mr. Georges Hébert who will remain a member of the Board. The Corporation also announces stock option grants to its directors and officers.

  • GlobeNewswire

    DIAGNOS Announces Voting Results of Annual Meeting of Shareholders

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the voting results of its annual and special meeting of shareholders held earlier today. Mr. Georges Hébert, Mr. André Larente, Dr. Reid Maclellan, Dr. Jean-François Yale and Mr. François Côté were elected as directors of the Corporation to hold office until the closing of the next annual meeting of the shareholders, subject to the By-laws of the Corporation.

  • GlobeNewswire

    DIAGNOS Announces Closing of a Private Placement

    DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces the closing of a private placement (“Private placement”) of 2,750,000 units (each a “Unit”) issued at $0.20 per Unit, for gross proceeds of $550,000, which represents $50,000 more than what was previously announced on September 13, 2019. Shares issued as part of the Private placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period ending January 16, 2020.

  • GlobeNewswire

    DIAGNOS Announces Private Placement

    BROSSARD, Quebec, Sept. 13, 2019 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical.

  • Should You Be Pleased About The CEO Pay At DIAGNOS Inc.'s (CVE:ADK)
    Simply Wall St.

    Should You Be Pleased About The CEO Pay At DIAGNOS Inc.'s (CVE:ADK)

    André Larente became the CEO of DIAGNOS Inc. (CVE:ADK) in 2004. First, this article will compare CEO compensation with...

  • GlobeNewswire

    DIAGNOS Receives Medical Device Marketing Authorization from the Saudi Food and Drug Authority to commercialize CARA in Saudi Arabia

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today Medical Device Marketing Authorization for the corporation’s CARA application from the Saudi Food and Drug Authority (SFDA). “Registering and receiving the authorization to market our CARA platform from the local health authorities is of the utmost importance for us and represents a key milestone as part of our commercialization plan in Saudi Arabia.

  • GlobeNewswire

    DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM

    Launched in June 2018 in collaboration with the ophthalmology and endocrinology department, the technology showcase has allowed more than a thousand patients from the CHUM to access screening technology. “This technological showcase is very important to us.  We have been able to demonstrate it’s capability and save vision of patients.  We continue to demonstrate our expertise to our future Canadian and international clients.

  • Here's Why DIAGNOS (CVE:ADK) Might Be Better Off Without Debt
    Simply Wall St.

    Here's Why DIAGNOS (CVE:ADK) Might Be Better Off Without Debt

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...